Eton Pharmaceuticals, Inc. has announced preliminary results from a pilot study evaluating its investigational drug ET-700, designed to treat Wilson disease. The findings, released on November 5, 2026, indicate that ET-700 offers improved gastrointestinal tolerability compared to the existing treatment, GALZIN. This news is significant for Eton as it seeks to establish a stronger foothold in the pharmaceutical preparations market, particularly in the treatment of rare diseases.

The study was a randomized, double-blind, placebo-controlled pilot that assessed the safety and efficacy of ET-700, an extended-release zinc acetate formulation. According to the results, only one of the twelve participants receiving ET-700 reported treatment-related adverse events, compared to eight out of twelve participants taking GALZIN. Additionally, the study measured hepatic copper uptake, a crucial factor in managing Wilson disease, showing a 12% decrease with ET-700 versus a 46% decrease with GALZIN.

Founded in Delaware, Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases. The company trades on the Nasdaq under the ticker symbol ETON and falls under the SIC classification of 2834, which covers pharmaceutical preparations. Recent filings include multiple 8-K forms, with the latest detailing the preliminary study results.

In the filing, Eton noted, "The study demonstrated improved gastrointestinal tolerability with ET-700 compared to GALZIN, with treatment-related adverse events reported in 1 of 12 participants receiving ET-700 compared to 8 of 12 participants receiving GALZIN." This finding is particularly relevant given the known gastrointestinal side effects associated with zinc treatments for Wilson disease.

The implications of these results could be significant for patients suffering from Wilson disease, a genetic disorder that leads to excessive copper accumulation in the body. The company's commitment to advancing additional formulations of ET-700 aims to enhance copper absorption inhibition while maintaining a favorable tolerability profile. Eton plans to evaluate these faster-release formulations in additional study arms in 2027.

Sean Brynjelsen, Chief Executive Officer of Eton Pharmaceuticals, expressed optimism about the results, stating, "The tolerability findings are exciting and reinforce our belief that a slower release zinc can improve tolerability, which is a notorious issue with zinc treatment." He added that the company aims to combine effective copper control with a favorable safety profile.

The filing does not specify what happens next, but the company is expected to proceed with further studies to refine ET-700's formulation and efficacy. As Eton Pharmaceuticals continues to innovate in the rare disease space, the results from this pilot study could pave the way for new treatment options for patients with Wilson disease.